Eisai Co. Ltd.

11/29/2021 | Press release | Distributed by Public on 11/28/2021 17:38

European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) for Patients With Certain Types of Endometrial CarcinomaFirst Combination of Tyrosine Kinase[...]

News release searchSearch